On November 7-8, 2018, a meeting of representatives of the national trial groups was held in Amsterdam in the Netherlands. CEEGOG was represented by Vít Weinberger (UH Brno, Czech Republic) and the CEEGOG administrative manager Mrs. Ivana Nohová.
The Engot Admin meeting was focused on budgeting a clinical trial, ENGOT monitoring network, and sharing group resources. Roxana Albu from EORTC talked about the General Data Protection Regulation (GDPR).
The ENGOT Administrative meeting was followed by the ENGOT assembly meeting. Vít Weinberger updated other ENGOT group representatives on the FERTISS trial. On behalf of the CEEGOG Chair, Mansoor Raza Mirza from NSGO introduced the planned SOV09 trial for which CEEGOG had been designated as the Lead group. The 16 ENGOT groups expressed their preliminary interest in trial participation.
The main topic of the ENGOT assembly meeting involved trial activities and regular update on clinical trial research conducted under the ENGOT umbrella. Mansoor Raza Mirza reported about the ESGO council meeting held in Berlin on November 1-2. Antonio González Martín talked about the planned ENGOT conference which should expand awareness about the ENGOT mission and projects, and increase commitments of the investigators.
More information may be provided by the CEEGOG office on request.
The GCIG Autumn meeting was held on October 17-18, 2018, in Munich.
CEEGOG was represented by its Chairman, the administrative manager Mrs. Ivana Nohová, and by Dr. Volha Matylevich from the N.N. Alexandrov National Cancer Center of Belarus in Minsk. Since a Pathology Brainstorming Session was scheduled during the meeting, the pathologist Pavel Dundr from the Pathology Institute in Prague attended the Session. The Session focused on imaging techniques, molecular imaging, advances in digital pathology and artificial intelligence for primary diagnostics in gynaecological pathology, and its opporunities for use in clinical trials. The participants were informed on itegrating molecular markers into clinical trials, and the minimal pathology requirements in clinical trials. The discussion was centered around new imaging and pathology priorities in clinical research.
We are pleased to let you know that CEEGOG has been approved as a provisional member of GCIG – the Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers.
The Gynecological Cancer InterGroup aims to promote and facilitate high quality clinical trials in order to improve the outcomes for women with gynecological cancer. CEEGOG could be interested in joining some of the GCIG protocols, and GCIG can be a good network for boosting your projects in the future.
After two years of provisional membership, a re-evaluation for full membership is conducted (which also applies to all full membership groups every two years). One criterion is that CEEGOG works as a group, which means that several CEEGOG centers participate in GCIG trials. We look forward to cooperating with your centers within the GCIG trials and projects!
David Cibula participated in the GCIG CCRN (Cervix Cancer Research Network) Education symposium where he introduced our collaborative group and activities. He talked about all CEEGOG academic trials, and about the CEEGOG responsibilities related to conducting the ENGOT trials in our region. He also mentioned the role of the CEEGOG office, and highligted the importance of Study coordinating training at the CEEGOG office in Prague.
CEEGOG has been expanding, and a well functioning network among 39 centers within 8 countries in Central and Eastern Europe has been established. It is our pleasure to invite for collaboration the newly approved sites to be involved in CEEGOG from Croatia, Macedonia, Serbia, Romania.
Page 4 of 7